Avenue Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ATXI Nasdaq 2834 http://www.avenuetx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Avenue Therapeutics Inc

Avenue Therapeutics Trades Higher After Phase 3 Success - Jun 3rd, 2019 10:05 am
Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain - Jun 3rd, 2019 5:00 am
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights - May 13th, 2019 5:30 am
Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors - Apr 30th, 2019 5:30 am
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights - Mar 12th, 2019 5:30 am
Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary) - Feb 11th, 2019 5:30 am
ATXI: How Much Are CVRs Worth? - Jan 28th, 2019 8:05 am
Stull, Stull & Brody Announces Class Action Suit on Behalf of Purchasers of the Securities of Avenue Therapeutics, Inc. (NasdaqCM: ATXI) - Jan 19th, 2019 4:45 pm
Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain - Dec 19th, 2018 6:00 am
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Avenue Therapeutics, Inc. - ATXI - Dec 12th, 2018 6:00 pm
ATXI: InvaGen Acquisition Spices Up Quarterly Report - Dec 3rd, 2018 7:15 am
Research Report Identifies Chicken Soup for the Soul Entertainment, Allied Motion Technologies, Bandwidth, Solid Biosciences, Avenue Therapeutics, and BeyondSpring with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement - Nov 21st, 2018 5:45 am
Avenue Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights - Nov 14th, 2018 2:30 pm
ATXI: InvaGen Capital Raise & Acquisition - Nov 13th, 2018 10:00 am
InvaGen (a Cipla subsidiary) Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the U.S. - Nov 13th, 2018 4:30 am
ATXI: Second Quarter 2018 Results - Aug 27th, 2018 11:45 am
Special Report: Biotech incubator taps investors through in-house brokerage - Aug 2nd, 2018 8:29 am